Novabay Pharmaceuticals Inc (NBY)


Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Novabay Pharmaceuticals Inc chart...

About the Company

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

CEO

Justin Hall

Exchange

NYSE MKT LLC

Website

http://novabay.com/

$21M

Total Revenue

56

Employees

$1M

Market Capitalization

-0.34

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $NBY News

Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call

1d ago, source:

Hello, and welcome to the NovaBay Pharmaceuticals fourth-quarter and full year 2023 financial results conference call. All participants will be in listen-only mode. (Operator Instructions). As a ...

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

15d ago, source:

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare ...

NovaBay Pharmaceuticals: Q4 Earnings Insights

1d ago, source:

NovaBay Pharmaceuticals NBY reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:05 PM. Here's what investors need to know about the announcement. NovaBay Pharmaceuticals beat estimated ...

NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended ...

14d ago, source: Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that ...

NovaBay Pharmaceuticals To Sell DERMAdoctor Skincare Business - Quick Facts

14d ago, source:

NovaBay Pharmaceuticals, Inc. (NBY) has entered into an agreement to sell its DERMAdoctor skincare business including all product ...

NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript

1d ago, source: Yahoo Finance

NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript March 26, 2024 NovaBay Pharmaceuticals, Inc. misses ...

NovaBay Pharmaceuticals Inc NBY

14d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript

1d ago, source: Seeking Alpha

Hello and welcome to the NovaBay Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

NovaBay Pharmaceuticals Inc NBY

14d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NovaBay Pharmaceuticals Inc.

13d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...